

00 (Beijing, China). Bacterial strains, plasmids, and primers used in this study are listed in Table S1. All restriction enzymes and PCR reagents were purchased from TaKaRa Biotechnology Co. Ltd (Dalian, China) and Sangon Biotech Co. Ltd (Shanghai, China), respectively. Standard protocols were applied for the *in vitro* DNA manipulation and purification. Luria--Bertani (LB) broth and agar were purchased from Beijing Dingguo Changsheng Biotechnology Co. Ltd (Beijing, China). The oligonucleotides were synthesized and purified by Sangon Biotech Co. Ltd (Shanghai, China). DNA sequencing was performed by Shanghai Sunny Biotech Co. Ltd (Shanghai, China). The *in vivo* expression of target genes was confirmed by western blotting with the rabbit anti-His antibody (1:1000 dilution; Sigma-Aldrich) at 24 h after transfection. Plasmids construction and recombinant protein purification {#mbo3597-sec-0004} ---------- The genes encoding *orf35* from *H. sinaii* J1-1 and *orf23* from *H. sinaii* HI01 were amplified from genomic DNA by PCR using primer pair *orf35*-*F*/*orf35*-*R* and *orf23*-*F*/*orf23*-*R*, respectively, and then were cloned into the pMD18-T vector to generate pMD18-*orf35* and pMD18-*orf23*. These recombinant plasmids were further inserted into *Escherichia coli* BL21(DE3)pLysS by using the Ligation Independent Cloning (LIC) method to obtain *E. coli* BL21(DE3)pLysS-*orf35* and *E. coli* BL21(DE3)pLysS-*orf23*. Recombinant *E. coli* BL21(DE3)pLysS-*orf35* and *E. coli* BL21(DE3)pLysS-*orf23* were cultivated in 2 × LB broth medium supplemented with 100 *μ*g/mL ampicillin at 37° 82157476af